Soluble markers of prostate cancer progression

Cancer Research Therapy and Control

Volumn 7, Issue 3, 1998, Pages 233-237

  Hoosein, Naseema ^a   Finn, Laury ^a   Hodges, Sherie ^a   Diaz, Miguel ^a   Abdul, Mansoor ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chromogranin A; Immunoglobulins; Soluble markers

Indexed keywords

CHROMOGRANIN A; IMMUNOGLOBULIN; TUMOR MARKER;

ADULT; AGED; CANCER GROWTH; CLINICAL ARTICLE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

EID: 0032429758     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Hoosein NM, Abdul M, McCabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L and Logothetis C. J. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urologie Oncology, (1)246-251, 1995.
2. Abdul M. Banks M and Hoosein NM. Urinary markers for prostate cancer. International Journal of Oncology, (8)735-739, 1996.
3. Hoosein NM, Abdul M and Logothetis CJ. Significance of neuroendocrine differentiation in prostatic carcinoma. The Cancer Journal, (9)291-295, 1996.
4. Deftos LJ, Nakada S, Burton DW, Di Sant'Agnese PA, Cockett ATK, Abrahamsson P-A. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology (48)58-62, 1996.
5. Cussenot O, Villette JM, Valeri A, Cariou G, Desgranchamps F. Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J. Urol. (155)1340-1343. 1996.
6. Sokoloff RL, Norton KC, Wolfert RL, Rittenhouse HG, Deftos LJ. Serum chromogranin A and PSA-forms in early-stage, untreated prostate cancers. J. Urol. 155. suppl. 696A# 1539, 1996.
7. Weinstein MH, Partin AW, Veltri RW, Epstein JI.Neuroendocrine differentiation in prostate cancer Enhanced prediction after radical prostatectomy. Human Pathology (27)683-687, 1996.
8. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY and Simons JW. Interleukin-6 A candidate mediator of human prostate cancer morbidity. Urology (45)542-549, 1995.
9. Rowley DR, Dang TD, McBride L, Gerdes MJ, Lu B and Larsen M. -2 Microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor pi action. Cancer Res (55)781-786, 1995.
10. Logothetis CJ and Hoosein NM. The inhibition of paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J. Cell. Biochem. Suppl. 16H 128-134, 1992.